latest news releases from the newsroom
Acura Pharmaceuticals, Inc.
Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
PALATINE, Ill. and BRISTOL, Tenn., June 17, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) today announced positive top-line results from Acura's pivotal Phase III study, AP-ADF-105 ("Study 105"). Both strengths of Acurox(tm) Tablets met the primary pain relief endpoint compared to placebo (p=.0001, and p less than.0001). The most prevalent reported adverse events in patients receiving Acurox(tm) Tablets were nausea, vomiting, dizziness, pruritis and flushing. Study 105 was conducted under the U.S. Food and Drug Administration ("FDA") Special Protocol Assessment ("SPA") provision. Acura and King expect to submit a New Drug Application ("NDA") for Acurox(tm) Tablets to the FDA by the end of this year with a targeted indication for the relief of moderate to severe pain where the use of an immediate release, orally administered, opioid analgesic tablet is appropriate.
Futuremedia Learning Event Shows Next Generation Learning Communities in Action
BRIGHTON, England, June 17, 2008 (PRIME NEWSWIRE) -- Futuremedia Learning, a leading e-learning provider and a division of Futuremedia plc (OTCBB:FMDAY), will showcase its work with clients in building successful Next Generation Learning Communities in an event held in London this June. Learning Communities in Action (26th June, Southbank Centre, London) is a knowledge-sharing workshop featuring client case studies and a presentation by the Bupa Learning & Development team.